Upfront Briefing
Capital markets ran hot today: Paragon spinout Mentari reverse-merged into InMed with a concurrent oversubscribed $290M PIPE, Relay paired positive vascular anomalies data with a $175M follow-on, and Regeneron seeded its next platform bet with up to $2.3B at Parabilis on the Helicon peptide platform. Healthcare bucked a risk-off tape on rising yields, biotech stayed selective with NBI flat and XBI lower, and the rest of the docket leaned toward financings, BD&L and a few quietly notable clinical reads (Wave, Merck, Vincentage).
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,353.6 |
(0.7%) |
7.2% |
| Nasdaq 100 |
28,818.8 |
(0.6%) |
14.3% |
| Russell 2000 |
2,747.1 |
(1.0%) |
9.5% |
| Healthcare (XLV) |
147.3 |
1.1% |
(5.3%) |
| Biotech (XBI) |
126.8 |
(0.7%) |
4.3% |
| Nasdaq Biotech (NBI) |
5,719.9 |
0.0% |
0.2% |
| Clinical Trials (BBC) |
40.5 |
(1.5%) |
7.7% |
|
- Healthcare bucked the broader risk-off tape, with XLV closing higher as defensives caught a bid into the 30-year yield spike (briefly above 5.19%, the highest since 2007) — large-cap pharma names within XLV (LLY, JNJ, ABBV, UNH, MRK ≈45% of the ETF) cushioned the move.
- Biotech stayed split: NBI finished flat while XBI slipped (0.7%), as rising real rates compressed long-duration biotech multiples and financing-heavy headlines reinforced overhang concerns at the smaller-cap end of the tape.
- Market data: U.S. close Tue 19-May-2026.
The Big 3
|
1
|
Mentari reverse-merges into InMed with $290M oversubscribed PIPE
|
- Paragon spinout Mentari Therapeutics is going public via an all-stock reverse merger with InMed (NASDAQ: INM), paired with an oversubscribed $290M private placement led by Fairmount with a16z Bio + Health, Wellington, Blackstone Multi-Asset, RTW, Vivo Capital, Janus Henderson and Perceptive. Combined-co pro forma equity value ~$421M; legacy InMed shareholders left with ~1.5%. Funded through 2028.
- Why it matters: Mentari pairs MT-001 (anti-PACAP mAb, CTA mid-2026) with MT-002 (CGRP × PACAP bispecific, CTA 1Q27) — the cleanest investor-grade bet yet on PACAP as the next migraine prevention axis beyond CGRP, which still leaves two-thirds of patients with incomplete control. The Fairmount-led crossover syndicate and reverse-merger structure is becoming the preferred route to public for high-conviction private biotech, sidestepping IPO-window risk. Shell risk is real but the $421M pro forma and two-year funding runway mitigate the near-term overhang.
- Source: Endpoints · BioPharma Dive
|
|
2
|
Relay's zovegalisib delivers in vascular anomalies; $175M follow-on launched same day
|
- Relay Therapeutics (RLAY) reported initial Phase 2 ReInspire data for zovegalisib (PI3Kα mutant-selective) in PIK3CA-driven vascular anomalies: 60% volumetric response across doses at 12 weeks (100% at 300mg; 57% at 400mg; 29% at lowest 100mg dose), with 89%/79% investigator- and patient-reported clinical improvement and a chronic-dosing-compatible safety profile. Shares jumped double-digits premarket; the company launched a $175M underwritten common-stock follow-on after-close (Jefferies / TD Cowen / Goldman Sachs / Guggenheim joint book-runners).
- Why it matters: A clean Phase 2 win validates PI3Kα mutant-selective inhibition over alpelisib's non-selective profile (which carries a broader hyperglycemia/AE burden) and meaningfully de-risks the 2L PIK3CA-mutated breast cancer Phase 3 ReDiscover-2, where zovegalisib already holds Breakthrough Therapy designation. The ability to tag a $175M follow-on into the data is the clearest possible read-through that biotech generalists are back and willing to fund on catalyst events.
- Source: PR (data) · PR (offering)
|
| 3 | Regeneron seeds $2.3B platform bet at Parabilis on Antibody-Helicon Conjugates |
- Regeneron is paying Parabilis Medicines (formerly FogPharma) $50M upfront plus a $75M equity commitment into Parabilis's next financing ($125M near-term total), with up to ~$2.2B in development, regulatory and commercial milestones plus tiered royalties to the low double-digits, across 5 initial targets. The collaboration centers on Helicon stabilised α-helical peptides and Antibody-Helicon Conjugates (AHCs) — designed to engage intracellular and flat-surface targets historically inaccessible to conventional biologics or small molecules.
- Why it matters: Arriving days after fianlimab's Phase 3 melanoma miss, this is Regeneron diversifying its oncology platform into a novel modality class — AHCs as ADC-like conjugates but with cell-penetrant peptide payloads targeting intracellular drivers. Parabilis closed a $305M Series F earlier in 2026 around its lead zolucatetide; the Regeneron pact franchises the Helicon platform without surrendering the lead asset, and validates AHCs as the next conjugate paradigm after classical ADCs.
- Source: Endpoints · PR
|
Everything Else that broke
- Wave Life Sciences' WVE-006 (GalNAc-RNA editing) hits MZ-like phenotype with monthly 400mg dosing in AATD — 71% Z-AAT reduction, restored dynamic AAT production; on track for mid-2026 FDA accelerated-approval feedback. — PR
- Merck's sac-TMT ADC scores first global Phase 3 win, ahead of schedule. — Endpoints
- Vincentage Pharma's oral GLP-1 VCT220 delivers 12.4% weight loss at 52 weeks in Phase 3 obesity trial; China NDA filing imminent. Note: Corxel holds ex-China rights as CX11, with U.S. Phase 2 readout later in 2026. — Fierce
- Co-Diagnostics announces $3M ATM private placement; signals thin cash cushion with runway and dilution overhang likely to persist. — PR
- BioArctic reports Q1 2026 interim results. — PR
- Implantica submits final FDA PMA response for RefluxStop. — PR
- Daiichi outlines strategy after ADC setbacks. — BioSpace
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Paragon-incubated Mentari Therapeutics reverse-merges into InMed Pharmaceuticals (NASDAQ: INM); concurrent oversubscribed $290M PIPE led by Fairmount (with a16z Bio + Health, Wellington, Blackstone Multi-Asset, RTW, Vivo Capital, Janus Henderson, Perceptive). Pro forma equity ~$421M; legacy INM holders ~1.5%, funded through 2028. — Endpoints
-
Regeneron / Parabilis Medicines: $50M upfront + $75M equity commitment ($125M near-term) + up to ~$2.2B milestones plus tiered royalties to low double-digits across 5 initial targets on Parabilis's Helicon peptide / Antibody-Helicon Conjugate platform. — Endpoints
-
Eton Pharmaceuticals (NASDAQ: ETON) secures exclusive U.S. commercialization rights to IMPAVIDO (miltefosine) from Knight Therapeutics affiliate; $4.25M in fixed fees over the term; rights take effect 26-Sep-2026. — PR
VC / Private Financings
-
Full-Life Technologies (radiotherapeutics, Suzhou / Gembloux): $150M financing ($110M Series D equity + $40M debt) led by Vivo Capital; joined by SK Biopharmaceuticals, Chengwei Capital, HSG, Junson Capital, Yunion. Advances [225Ac]-FL-020 (prostate) and [225Ac]-FL-261 (solid tumors) plus Belgium GMP actinium-225 manufacturing facility. — PR
-
Accro Bioscience (immune-mediated diseases, Suzhou): $50M Series C led by OrbiMed; joined by TCG Crossover, Lilly Asia Ventures, Cenova Capital (existing: SCGC, Oriza Holdings). Funds Phase IIb of AC-101 (RIPK2 inhibitor) in moderate-to-severe ulcerative colitis. — PR
-
Oorja Bio launches with $30M Series A from Westlake BioPartners (sole founding investor); founded by Acceleron alumni Sujay Kango (CEO) and Janethe Pena (CMO). Advancing ORJ-001, a first-in-class subcutaneous β1-integrin agonist peptide targeting AEC2 cells, into Phase 2 IPF this year. — Endpoints
IPOs / Follow-Ons
-
Relay Therapeutics (RLAY) launched a $175M underwritten common-stock follow-on (15% greenshoe) into positive Phase 2 zovegalisib data; Jefferies / TD Cowen / Goldman Sachs / Guggenheim joint book-runners. — PR
-
Tarsier Pharma (TARX) set IPO terms: $45M, 5M shares at $8–$10 ($294M fully diluted mkt cap at midpoint), NYSE American; Konik Capital Partners sole bookrunner. Lead asset TRS01 — steroid-free dazdotuftide eye-drop for non-infectious anterior uveitis with uveitic glaucoma. — Renaissance Capital
-
Annovis launches proposed public offering of common stock and accompanying warrants — overhang expected until cleaner clinical catalysts. — PR
|
